Clinical Case Highlights Potential of Serration Remodeling Therapy in PAD

According to a recent LinkedIn post from Cagent Vascular Inc, a clinical case involving a 68‑year‑old high‑risk patient with a chronic toe ulcer and heavily calcified tibial vessels is highlighted. The patient reportedly had recurrent disease and two recent POBA failures, with a low baseline toe pressure and abnormal ankle‑brachial index (ABI).

The post describes the use of Serration Remodeling Therapy (SRT), after which ABI was said to improve toward a more normal range at 60 days, accompanied by increased toe pressure and complete wound healing. The company’s LinkedIn content suggests that SRT may enhance vessel compliance and sustained perfusion in challenging peripheral artery disease cases.

For investors, these reported outcomes may indicate growing clinical validation for Cagent Vascular’s technology in peripheral artery disease and critical limb‑threatening ischemia. If similar results are reproduced in larger datasets, this could support broader adoption, reimbursement traction, and strengthen the company’s competitive position in limb‑salvage interventions.

The shared link to a broader series of patient outcomes implies an effort to build an evidence base that could appeal to vascular specialists and hospital decision‑makers. Over time, stronger real‑world data may translate into higher procedure volumes, potential partnerships, and a more favorable revenue outlook, though regulatory, clinical, and commercialization risks remain.